Genetic markers in oligodendroglial tumours

Radiology and Oncology

Volumn 44, Issue 1, 2010, Pages 13-18

  Velnar, Tomaz ^a,b   Smrdel, Uros ^b   Popovic, Mara ^c   Bunc, Gorazd ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Chemotherapy; Genetic markers; Oligodendroglioma; Prognosis

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GROWTH FACTOR; LOMUSTINE; MELPHALAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; DRUG SENSITIVITY; GENE MUTATION; GENETIC MARKER; HUMAN; METHYLATION; OLIGODENDROGLIOMA; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 77950160417     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-010-0007-y     Document Type: Review

References (64)

1. Gilbert MR, Lang FF. Management of patients with low-grade gliomas. Neurol Clin 2007; 25: 1073-1088
2. Strojnik T, Gornik-Kramberger K. [Stereotactic biopsy of brain tumours - Maribor experience with MHT stereotaxy system]. [Slovenian]. Zdrav Vestn 2008; 77: 601-608
3. Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME. Advances in brain tumor surgery. Neurol Clin 2007; 25: 975-1003.
4. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol 2003; 60: 443-456
5. Strojnik A. Search of the shortest regimen: fractionation of a fully isoeffective combination of hyperfractionated and hypofractionated treatment. Radiol Oncol 2008; 42: 170-172
6. Heikal AA, Wachowicz K, Thomas SD, Fallone BG. A phantom to assess the accuracy of tumor delineation using MRSI. Radiol Oncol 2008; 42: 232-239
7. Giampaoli S. Epidemiology of major age-related diseases in women compared to men. Aging (Milano) 2000; 12: 93-105.
8. Pytel P, Lukas RV. Update on diagnosic practice: tumors of the nervous system. Arch Pathol Lab Med 2009; 133: 1062-1077
9. van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol 2008; 66: 262-272
10. Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 2006; 60: 99-111.
11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon 2007: WHO, IARC; 2007. p. 53-67.
12. Ohgaki H Epidemiology of brain tumors. Methods Mol Biol 2009; 472: 323-342
13. Cancer incidence in Slovenia 2005. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Slovenia; 2008.
14. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.
15. Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurg Focus 2005; 19: E5.
16. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4: 278-299
17. Hilton DA, Melling C. Genetic markers in teh assesment of intrinsic brain tumours. Current Diagnostic Pathology 2004; 10: 83-92.
18. Scelsi R. Epidemiology of cerebral gliomas. Minerva Med 1984; 75: 1259-1263
19. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97-117.
20. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-2578
21. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002; 58: 111-117
22. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003; 60: 443-456
23. Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, et al. Histological and molecular classification of gliomas. Rev Neurol (Paris) 2008; 164: 505-515
24. Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G. Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien) 2008; 150: 699-703.
25. Volavsek M, Lamovec J, Popović M. Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract 2009; 205: 502-507
26. Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009; 14: 155-163
27. van den Bent MJ. Diagnosis and management of oligodendroglioma. Semin Oncol 2004; 31: 645-652
28. Franko A, Holjar-Erlic I, Miletic D. Lateral ventricle epidermoid. Radiol Oncol 2008; 42: 66-68
29. Bisof V, Juretic A, Saric N, Melada A, Perkovic Z, Rados M, et al. Pituitary metastasis of renal cell carcinoma: a case report. Radiol Oncol 2008; 42: 225-231
30. Liigant A, Haldre S, Oun A, Linnamägi U, Saar A, Asser T, et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001; 45: 46-51.
31. Engelhard HH. Current diagnosis and treatment of oligodendroglioma. Neurosurg Focus 2002; 12: E2.
32. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 1994; 35: 1018-1035
33. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-468
34. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994; 30: 567-573
35. Paleologos NA, Cairncross JG. Treatment of oligodendroglioma: an update. Neuro Oncol 1999; 1: 61-68
36. Bullard DE, Rawlings CE 3rd, Phillips B, Cox EB, Schold SC Jr, Burger P, et al. Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 1987; 60: 2179-2188
37. van den Bent MJ. Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova) 2000; 10: 108-118
38. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendrogliomav. Expert Rev Anticancer Ther 2001; 1: 348-356
39. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-518
40. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 2004; 5: 295-306.
41. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762-2771
42. Michotte A, Chaskis C, Sadones J, Veld PI, Neyns B. Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: Report of a unique case successfully treated with Temozolomide. J Neurol Sci 2009; 287: 267-270
43. Morrison T, Bilbao JM, Yang G, Perry JR. Bony metastases of anaplastic oligodendroglioma respond to temozolomide. Can J Neurol Sci 2004; 31: 102-108
44. van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 2007; 25: 1089-1109
45. Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 2003; 97: 2352-2358
46. Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 2004; 100: 807-813
47. Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009; 115: 1734-1743
48. Gadji M, Fortin D, Tsanaclis AM, Drouin R. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet 2009; 194: 12-22.
49. Stupp R, Hegi ME. Neuro-oncology: oligodendroglioma and molecular markers. Lancet Neurol 2007; 6: 10-12
50. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7: 839-845
51. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-319
52. Ducray F, Idbaih A, de Reyniès A, Bièche I, Thillet J, Mokhtari K, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008; 7: 41.
53. Riemenschneider MJ, Koy TH, Reifenberger G. Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol 2004; 107: 277-282
54. Li H, Lu Y, Smith HK, Richardson WD. Olig1 and Sox10 interact synergistically to drive myelin basic protein transcription in oligodendrocytes. J Neurosci 2007; 27: 14375-14382
55. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007; 131: 242-251
56. Glioma meta-analysis trialists group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018
57. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-2722
58. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24: 4746-4753
59. Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 2007; 19: 606-611
60. Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris) 2008; 164: 595-604.
61. Sonabend AM, Lesniak MS. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions. Expert Rev Neurother 2005; 5: S25-32.
62. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007; 87: 392-397
63. Mueller WC, von Deimling A. Gene regulation by methylation. Recent Results Cancer Res 2009; 171: 217-239
64. Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12: 279-292